治疗前肺功能检查在CD19 CAR-T细胞治疗的B细胞淋巴瘤中效用有限
该单中心回顾性分析纳入192例接受自体CD19 CAR-T治疗的复发/难治性B细胞淋巴瘤患者,评估治疗前肺功能检查(PFT)及基于HCT-CI的肺部合并症分级对疗效与毒性的预测价值。分类变量FEV1、DLCO及肺部合并症等级与总缓解率、免疫毒性、总生存和无进展生存均无显著相关;仅连续变量FEV1在多变量模型中与无进展生存期缩短相关(HR 0.87,95%CI 0.78-0.96,P=0.007)。
要点
- 分类FEV1、DLCO及肺部合并症等级不能预测CAR-T疗效或毒性。
- 连续FEV1与无进展生存期相关(HR 0.87,95%CI 0.78-0.96,P=0.007)。
- 肺功能指标与总生存、总缓解率及严重免疫毒性均无显著相关。
核心结论
- 分类FEV1、DLCO和肺部合并症等级未能预测疗效或毒性;连续FEV1是唯一与无进展生存期相关的肺功能指标,且独立于总生存或严重毒性。
研究设计与样本
- 单中心回顾性分析,纳入192例接受商业和即时制备CD19 CAR-T治疗的复发/难治性B细胞淋巴瘤患者。
- 治疗前进行肺功能检查,并根据FEV1和单次呼吸一氧化碳弥散量(DLCO)按HCT-CI将患者分为3个肺部合并症等级。
- 采用单变量和多变量Cox回归、逻辑回归、Kaplan-Meier法和样条模型评估结局与毒性。
主要发现
- 肺部合并症指标与总缓解率或免疫毒性(包括细胞因子释放综合征分级>2和免疫效应细胞相关神经毒性分级>2)无相关性。
- 分类FEV1、DLCO和肺部合并症水平与总生存无相关性(P分别为0.3、0.4、0.6)。
- 分类FEV1、DLCO和肺部合并症水平与无进展生存无相关性(P分别为0.058、>0.9、0.2)。
- 连续FEV1在多变量模型中与无进展生存期缩短相关(HR 0.87,95%CI 0.78-0.96,P=0.007)。
- 样条模型显示FEV1与无进展生存期呈线性相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pulmonary function tests (PFTs) are recommended for hematopoietic cell transplantation (HCT) evaluation. However, their prognostic value in chimeric antigen receptor T-cell (CAR-T) therapy remains unclear. We assessed the predictive significance of PFTs and pulmonary comorbidity classifications, per the Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI), in patients with B-cell lymphoma undergoing autologous CD19 CAR-T therapy. Single-center retrospective analysis encompassing 192 patients with relapsed/refractory B-cell lymphoma (BCL), treated with commercial and point-of-care CD19-directed CAR-T therapy. Pretherapy PFTs were conducted, and patients were stratified into 3 HCT-CI-based pulmonary comorbidity grades, using forced expiratory volume in 1 second (FEV1) and single-breath diffusing capacity for carbon monoxide (DLCO). Outcomes and toxicities were evaluated using univariate and multivariable Cox regression, logistic regression, Kaplan-Meier method, and spline models. Pulmonary comorbidity measures were not correlated with overall response rates or immune toxicities, including cytokine release syndrome grade >2 and immune effector cell-associated neurotoxicity grade >2. Categorical FEV1, DLCO, and pulmonary comorbidity level did not correlate with overall survival (OS; P = .3, P = .4, P = .6, respectively) or progression-free survival (PFS; P = .058, P > .9, P = .2, respectively). FEV1 as a continuous measure was associated with reduced PFS in a multivariable model (hazard ratio, 0.87; 95% confidence interval, 0.78-0.96; P = .007). Spline modeling demonstrated a linear correlation between FEV1 and PFS. Categorical FEV1, DLCO, and pulmonary comorbidity level failed to predict therapy efficacy or toxicity. FEV1 as a continuous measure was the sole PFT measure associated with PFS, independent of OS or severe toxicities.
引用
- Sdayoor I, Shouval R, Fried S, et al. Pretreatment pulmonary function testing has limited utility in B-cell lymphoma treated with CD19 CAR T cells. Blood Adv. 2025. PMID: 39774788. doi:10.1182/bloodadvances.2024014488
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。